| Identification | Back Directory | [Name]
Benzamide, N-[(3S,4S)-4-(3,4-difluorophenyl)-3-piperidinyl]-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)- | [CAS]
2241232-43-7 | [Synonyms]
Hu7691 free base
Benzamide, N-[(3S,4S)-4-(3,4-difluorophenyl)-3-piperidinyl]-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)- | [Molecular Formula]
C22H21F3N4O | [MOL File]
2241232-43-7.mol | [Molecular Weight]
414.42 |
| Hazard Information | Back Directory | [Uses]
Hu7691 free base is an orally active, selective Akt inhibitor with IC50s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 free base inhibits tumor growth and enables decrease of cutaneous toxicity in mice[1]. | [in vivo]
Hu7691 free base (12.5-50 mg/kg/day; i.g.; for 22 days) shows dose-dependent tumor growth inhibition[1].
Hu7691 free base (15 mg/kg; oral) has a T1/2 of 8.68 hours, a Cmax of 171.17 ng/mL and an AUC of 2820.64 ng/mL h in rats[1].
Hu7691 free base (2 mg/kg; iv) has a T1/2 of 6.24 hours, a Cmax of 207.52 ng/mL and an AUC of 532.87 ng/mL h in rats[1].
Hu7691 free base (20 mg/kg; oral) has a T1/2 of 16.7 hours, a Cmax of 905.65 ng/mL and an AUC of 36303 ng/mL h in beagle dog (male, 40 weeks old, 8-10 kg)[1].
| Animal Model: | Balb/c mice (nu/nu, female, 3-4 weeks old, 20-25 g) with 786-O and KHOS xenograft[1] | | Dosage: | 12.5, 25, 50 mg/kg | | Administration: | Oral; once daily for 22 days | | Result: | Showed dose-dependent tumor growth inhibition.
|
| Animal Model: | SD rats (male, 8 weeks old, 250-300 g)[1] | | Dosage: | 15 mg/kg (Pharmacokinetic Analysis) | | Administration: | Oral | | Result: | Had a T1/2 of 8.68 hours, a Cmax of 171.17 ng/mL and an AUC of 2820.64 ng/mL?h.
|
| [IC 50]
Akt1: 4.0 nM (IC50); Akt2: 97.5 nM (IC50); Akt3: 28 nM (IC50); PKA: 11 nM (IC50); PKCη: 629 nM (IC50); ROCK1: 354 nM (IC50); RSK1: 756 nM (IC50); p70S6K: 229 nM (IC50) | [References]
[1] Jinxin Che, et al. Discovery of N-((3 S,4 S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1 H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity. J Med Chem. 2021 Aug 26;64(16):12163-12180. DOI:10.1021/acs.jmedchem.1c00815 |
|
|